Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation

By Katz Matthew  

Annals of Surgical Oncology, Vol. 17, Iss. 7, 2010-07 ,pp. : 1794-1801

Springer Publishing Company

Access to resources Recommend Favorite

CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy

By Hartwig Werner   Strobel Oliver   Hinz Ulf   Fritz Stefan   Hackert Thilo   Roth Constanze   Büchler Markus   Werner Jens  

Annals of Surgical Oncology, Vol. 20, Iss. 7, 2013-07 ,pp. : 2188-2196

Springer Publishing Company

Access to resources Recommend Favorite

Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine

By Saad Everardo   Machado Marcel   Wajsbrot Dalia   Abramoff Roberto   Hoff Paulo   Tabacof Jacques   Katz Artur   Simon Sergio   Gansl René  

International Journal of Gastrointestinal Cancer, Vol. 32, Iss. 1, 2002-08 ,pp. : 35-41

Humana Press, Inc

Access to resources Recommend Favorite

RE: CA 19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Preoperative Therapy

By Bold Richard  

Annals of Surgical Oncology, Vol. 20, Iss. 7, 2013-07 ,pp. : 2108-2110

Springer Publishing Company

Access to resources Recommend Favorite

Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma

By Maithel Shishir  

Annals of Surgical Oncology, Vol. 15, Iss. 12, 2008-12 ,pp. : 3512-3520

Springer Publishing Company

Access to resources Recommend Favorite